更新于：2024-11-01

Telmesteine

替美司坦

更新于：2024-11-01

概要

概要

基本信息

药物类型

小分子化药

别名

Telmesteine (INN)、Muconorm

+ [1]

靶点

Akt-1 x IKKα x MMP9

作用机制

Akt-1抑制剂(丝氨酸/苏氨酸蛋白激酶AKT抑制剂)、IKKα inhibitors(component of inhibitor of nuclear factor kappa B kinase complex inhibitors)、MMP9抑制剂(基质金属蛋白酶-9抑制剂)

治疗领域

呼吸系统疾病

在研适应症

咳嗽

非在研适应症-

原研机构-

在研机构-

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C7H11NO4S

InChIKeyXBJWOGLKABXFJE-YFKPBYRVSA-N

CAS号122946-43-4

关联

100 项与替美司坦相关的临床结果

登录后查看更多信息

100 项与替美司坦相关的转化医学

登录后查看更多信息

100 项与替美司坦相关的专利（医药）

登录后查看更多信息

项与替美司坦相关的文献（医药）

2021-01-01·Wound Repair and Regeneration3区 · 医学

Functional recovery in human partial thickness skin wounds after application of multicomponent hydrolipidic film (MAS063DP): A prospective, open‐label, comparative clinical trial

3区 · 医学

Article

作者: Lin, Erh‐Ti ; Chang, Chang‐Cheng ; Chiang, Hsiu‐Mei ; Chen, Wei‐Kung ; Lin, Bor‐Shyh ; Wang, Yen‐Jen ; Tsai, Li‐Cheng

AbstractAcute and minor skin wounds are common in daily life. However, in clinical practice, after initial management in the acute phase, the wounds are managed mainly through observation, and the patients are usually lost to follow‐up. Considering a multicomponent hydrolipidic dressing (MAS063DP) long‐known for its safe application in eczema and recently in laser‐induced wounds, we aimed to evaluate its ability in functional recovery of impaired skin integrity during wound healing. Sixteen patients (N = 16) were enrolled and completed (n = 8 vs n = 8) this prospective, open‐label, vehicle‐controlled clinical trial with 12‐week follow‐up. Transepidermal water, skin viscoelasticity and bioimpedance analysis were measured initially, at the 1st, 4th, 8th, and 12th weeks. Improvements in these parameters were greater in the MAS063DP group (from 31.4 ± 9.0 to 16.4 ± 4.3 g/m2 h, P < .001; from 77 ± 16% to 88 ± 9%, P < .05; from 4182 ± 3823 to 2644 ± 1772 Ω) than in the white petrolatum group. No significant adverse events occurred, and all participants were more satisfied with the intervention. In this study, MAS063DP can restore skin integrity and reinstitute physiologic function as a feasible and safe intervention more markedly than management through observation during the healing process by providing protective hydrolipidic layer on the skin with simultaneous anti‐inflammatory and antioxidant activities from its key ingredients such as glycyrrhetinic acid, Vitis vinifera, telmesteine, and vitamins C and E.

2018-05-01·Italian Journal of Dermatology and Venereology4区 · 医学

Evidence-based treatment of atopic dermatitis with topical moisturizers

4区 · 医学

Review

作者: Dinotta, Franco ; Micali, Giuseppe ; Cannarella, Rossella ; Paternò, Valentina ; Lacarrubba, Francesco

Skin barrier restoration represents the mainstay of the treatment of atopic dermatitis and the use of moisturizers is recommended by several international guidelines. The aim of the study was to investigate through an evidence-based medicine analysis the effectiveness and safety of different moisturizing products available for a non-pharmacological treatment of atopic dermatitis. A total of 92 randomized controlled trials (RCTs) have been identified and analyzed. The results confirm the presence of a reasonable number of studies highlighting moisturizers safety and effectiveness in the treatment of atopic dermatitis by improving disease severity, increasing the time of relapse and reducing the time of flares. Moisturizers containing urea, glycerin or glycyrrhetinic acid seem to show the greater evidence of efficacy being supported by more clinical trials. Among the existing moisturizers, those containing a single agent generally work although the heterogeneity of RCTs does not allow reaching more definitive conclusions. Moisturizers made of a mixture of substances seem to be more effective thanks to the presence of different active substances that may exert a synergistic effect. A meta-analysis of 4 RCTs confirms the efficacy of a medical device containing glycyrrhetinic acid, hyaluronic acid, shea butter, telmesteine, and vitis vinifera in the treatment of atopic dermatitis.

2009-06-01·Journal of drugs in dermatology : JDD4区 · 医学

Treatment of pruritus in mild-to-moderate atopic dermatitis with a topical non-steroidal agent.

4区 · 医学

Article

作者: De Micheli, Paolo ; Lunardon, Luisa ; Schianchi, Rossana ; Veraldi, Stefano

Atopiclair (Zarzenda) is a topical non-steroidal anti-inflammatory agent for the treatment of allergic diseases of the skin. Three main ingredients are contained in this product: glycyrrhetinic acid, telmesteine and Vitis vinifera extracts. Other ingredients include: allantoin, alpha-bisabolol, capryloyl glycine, hyaluronic acid, shea butter and tocopheryl acetate. Two previous randomized, double-blind, vehicle-controlled clinical studies provided evidence that Atopiclair is effective in the treatment of atopic dermatitis. This article presents an open, multicenter, sponsor-free, study on the anti-pruritic activity of this product in adult patients with mild-to-moderate atopic dermatitis. The Median Visual Analogue Scale (VAS) values were: at the start of the study (TO), median VAS was 48.5 mm; three weeks later (T1), median VAS was 34.1 mm (-14.4 mm from baseline); six weeks later (T2), median VAS was 24.6 mm (-23.9 mm from baseline). Statistical analysis revealed that differences between TO versus T1, TO versus T2 and T1 versus T2 were highly significant (p<0.001). Side effects (local burning) were relatively common, although mild in severity. On the basis of the results of this study, Atopiclair showed efficacy in relief of pruritus in adult patients with mild-to-moderate atopic dermatitis.

100 项与替美司坦相关的药物交易

登录后查看更多信息